Supernus Pharmaceuticals
SUPN
226 hedge funds and large institutions have $1.67B invested in Supernus Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 74 increasing their positions, 83 reducing their positions, and 27 closing their positions.
26% more call options, than puts
Call options by funds: $2.42M | Put options by funds: $1.93M
19% more capital invested
Capital invested by funds: $1.4B → $1.67B (+$272M)
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
1.45% more ownership
Funds ownership: 100.82% → 102.27% (+1.5%)
1% more funds holding
Funds holding: 223 → 226 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
11% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 83
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$36.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$10.8M |
| 4 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$9.04M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$6.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$25.5M |
| 2 |
Renaissance Technologies
New York
|
-$7.48M |
| 3 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$7.06M |
| 4 |
Two Sigma Investments
New York
|
-$6.49M |
| 5 |
PP
Prudential plc
London, England,
United Kingdom
|
-$6.34M |
SUPN Hedge Fund Activity: Q2 2021 in Review
226 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2021, worth a combined $1.67B — up 19% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SUPN positions and 27 closed out — a net gain of 4 holders — while 74 added to existing stakes and 83 trimmed.
The largest buyer was Loomis, Sayles & Company, adding an estimated $36.4M. The largest seller was LSV Asset Management, cutting an estimated $25.5M.
- 226 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2021, up from 223 in Q1 2021.
- Funds reported $1.67B of Supernus Pharmaceuticals stock for Q2 2021, up 19% quarter-over-quarter.
- 31 funds opened new Supernus Pharmaceuticals positions in Q2 2021 and 27 closed out, a net change of +4 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2021 was Loomis, Sayles & Company, an estimated $36.4M added.
- The largest Supernus Pharmaceuticals seller in Q2 2021 was LSV Asset Management, an estimated $25.5M sold.
Based on aggregated 13F filings for Q2 2021.